Previous 10 | Next 10 |
Greenpro Capital (NASDAQ: GRNQ ) -24% . More news on: Greenpro Capital Corp., Euroseas Ltd., Zafgen, Inc., Stocks on the move, , Read more ...
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for potential long-lasting...
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed thro...
Be The Match BioTherapies will provide allogeneic cellular source material to NantKwest for clinical trial addressing primary cause of COVID-19 fatality Be The Match BioTherapies ® , an organization offering solutions for companies developing and commercializing cell and gene th...
Sorrento Therapeutics (NASDAQ: SRNE ) +36% in reaction to reports that it has discovered an antibody, dubbed STI-1499, that, it says, can provide 100% inhibition of COVID-19. More news on: Sorrento Therapeutics, Inc., Moderna, Inc., Fulgent Genetics, Inc., Stocks on the ...
Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm Trial anticipated to initiate in Los Angeles area hospitals in Q2 Proprietary automated “GMP...
Cassava Sciences (NASDAQ: SAVA ) -82% after Alzheimer's candidate flunks mid-stage study. More news on: Cassava Sciences, Inc., Synthesis Energy Systems, Inc., Creative Realities, Inc., Stocks on the move, , Read more ...
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer patien...
NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20 pm ET. A live audio webcast of the confere...
Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +100% . More news on: Sonnet BioTherapeutics Holdings, Inc., MEI Pharma, Inc., NantKwest, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
NantKwest Company Name:
NK Stock Symbol:
NASDAQ Market:
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...